HomeList of TitleSearchContact Us

Open Journal of Hematology

ISSN: 2075-907X
Volume 8, 2017

Indexed in:

Open Journal of Hematology, 2015, 6-4 [Research Article]

Adverse effects of Imatinib Mesylat: 5-year follow-up of 55 patients with chronic myeloid leukemia in Dakar (Sénégal)

Fatou Samba Diago Ndiaye, Seynabou Fall, Abibatou Sall, Awa Oumar Touré, Atoumane Faye, Nafissatou Diagne, Abdoulaye Pouye

Unit of Hematology in Le Dantec hospital, Cheikh Anta Diop University, Dakar, Senegal

Corresponding Author & Address:

Fatou Samba Diago Ndiaye*
Unit of Hematology in Le Dantec hospital, Cheikh Anta Diop University, Avenue Pasteur BP : 10599  Dakar Liberte, Dakar, Senegal; Phone: 221 775299844/ +221776124484; Email: kinepierre1@yahoo.fr

Article History:
Published: 9th May, 2015   Accepted: 9th May, 2015
Received: 13th January, 2015      

© Ndiaye et al.; licensee Ross Science Publishers

ROSS Open Access articles will be distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work will always be cited properly.

Keywords: chronic myeloid leukemia, Imatinib Mesylat, adverse effects, Dakar


Introduction: Imatinibmesylate has significantly improved the survival of patients with chronic myeloid leukemia, with less toxicity than previous chemotherapy.

Methods: We describe the profile of hematological side effects or not Imatinib mesylate; through a retrospective study of 1 June 2006 to 31 June 2011, led to the unity of Hematology Le Dantec in Dakar (Senegal) in patients with chronic myeloid leukemia, imatinibmesylate treated. Chemotoxicity was classified according to WHO grades.

Results: A total of 55 patients followed; 24 (43.6%) had non-hematological side effects of grade 1-2, dominated by diffuse depigmentation (15 cases), followed by musculoskeletal symptoms (10 cases), digestive (6 cases), infection (4 cases) and secondary amenorrhea (1 case). Cytopenias observed in 34 patients, were more grade 1-2 (58.2%).

Conclusion: The side effects are common, rarely severe as reported in the literature. Our study is unique in the high frequency of diffuse depigmentation unlike western series.

©2017 Ross Science Publishers